Spyre Therapeutics Prices Upsized $403M Offering of 6.5M Shares
Spyre Therapeutics has priced an upsized public offering of 6.5 million shares of common stock at $62.00 each, generating approximately $403.0 million in gross proceeds. The underwriters hold a 30-day option to purchase up to an additional $60.5 million of shares, with closing expected around April 16, 2026.
1. Offering Terms
Spyre Therapeutics is selling 6,500,000 shares of common stock at $62.00 per share, resulting in gross proceeds of approximately $403.0 million before underwriting discounts, commissions and other expenses. The company granted underwriters a 30-day option to purchase up to an additional $60.5 million of shares at the public offering price, less the underwriting discount.
2. Closing and Underwriting
The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI and Guggenheim Securities, LLC are the joint book-running managers, with LifeSci Capital LLC acting as passive bookrunner.